Emily K. Slotkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emily K. Slotkin has a total of 413 co-authors. Here are the top co-authors by number of shared publications:
Marc Ladanyi
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York City, USA
56 shared publications- Anita S. Bowman
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
44 shared publications - Paul A. Meyers
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
39 shared publications - Marissa S. Mattar
Memorial Sloan Kettering Cancer Center 1 Department of Pathology and Laboratory Medicine New York, New York
36 shared publications - William D. Tap
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
36 shared publications Lee Spraggon
34 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-15
Paediatric therapeutic development workshop on desmoplastic small round cell tumours
- 14 October 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-15
Open AccessPaediatric therapeutic development workshop on desmoplastic small round cell tumours
- Open Access
Mifamurtide for Osteosarcoma in the United States: A Single-Center Real-World Experience
Purpose: Mifamurtide (liposomal muramyl tripeptide phosphatidylethanolamine [L-MTP-PE]) is approved in many countries for osteosarcoma but remains unavailable for routine use in the United States (US). We describe the feasibility and outcomes of patients with osteosarcoma treated with mifamurtide at Memorial Sloan Kettering Cancer Center (MSK) through expanded access (EAP) and compassionate use (SPU) pathways. Methods: Medical records were retrospectively reviewed for patients with completely resected, high-grade osteosarcoma treated with mifamurtide at MSK from 2016–2026 through EAP or SPU protocols. Mifamurtide 2 mg/m² was administered intravenously twice weekly for 12 weeks, followed by weekly administration for 24 weeks. Outcomes were evaluated by treatment setting and, for upfront therapy, metastatic status and histologic necrosis. Results: Fifty-seven patients received mifamurtide (median age, 14 years; range, 2-60); 72% had localized and 28% metastatic disease at diagnosis. No serious adverse events were considered possibly or probably related to mifamurtide, and no new grade 3-4 safety signals emerged. Five patients with localized disease and ≥90% necrosis at resection had no events, with 100% progression-free survival (PFS) and overall survival (OS) at median follow-up of 29 months. Among 22 patients with localized disease and <90% necrosis treated upfront, PFS was 82%, 66%, and 59% at 12, 24, and 48 months, respectively; OS was 95% at 12, 24, and 60 months. Among 8 patients with metastatic disease treated upfront, PFS was 73%, 58%, and 39% at 12, 24, and 36 months, respectively; OS was 100%, 86%, and 86%. Among 22 patients treated after relapse, PFS was 34%, 23%, and 17% at 12, 24, and 36 months, respectively; OS was 91%, 70%, and 35% at 12, 24, and 60 months. Conclusions: In this real-world US cohort, mifamurtide was feasible and safe to administer. Despite limitations of the EAP/SPU setting, single-institution administration, and patient heterogeneity, overall survival outcomes were encouraging.
Open AccessMifamurtide for Osteosarcoma in the United States: A Single-Center Real-World Experience
Purpose: Mifamurtide (liposomal muramyl tripeptide phosphatidylethanolamine [L-MTP-PE]) is approved in many countries for osteosarcoma but remains unavailable for routine use in the United States (US). We describe the feasibility and outcomes of patients with osteosarcoma treated with mifamurtide at Memorial Sloan Kettering Cancer Center (MSK) through expanded access (EAP) and compassionate use (SPU) pathways. Methods: Medical records were retrospectively reviewed for patients with completely resected, high-grade osteosarcoma treated with mifamurtide at MSK from 2016–2026 through EAP or SPU protocols. Mifamurtide 2 mg/m² was administered intravenously twice weekly for 12 weeks, followed by weekly administration for 24 weeks. Outcomes were evaluated by treatment setting and, for upfront therapy, metastatic status and histologic necrosis. Results: Fifty-seven patients received mifamurtide (median age, 14 years; range, 2-60); 72% had localized and 28% metastatic disease at diagnosis. No serious adverse events were considered possibly or probably related to mifamurtide, and no new grade 3-4 safety signals emerged. Five patients with localized disease and ≥90% necrosis at resection had no events, with 100% progression-free survival (PFS) and overall survival (OS) at median follow-up of 29 months. Among 22 patients with localized disease and <90% necrosis treated upfront, PFS was 82%, 66%, and 59% at 12, 24, and 48 months, respectively; OS was 95% at 12, 24, and 60 months. Among 8 patients with metastatic disease treated upfront, PFS was 73%, 58%, and 39% at 12, 24, and 36 months, respectively; OS was 100%, 86%, and 86%. Among 22 patients treated after relapse, PFS was 34%, 23%, and 17% at 12, 24, and 36 months, respectively; OS was 91%, 70%, and 35% at 12, 24, and 60 months. Conclusions: In this real-world US cohort, mifamurtide was feasible and safe to administer. Despite limitations of the EAP/SPU setting, single-institution administration, and patient heterogeneity, overall survival outcomes were encouraging.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Optimization efforts to procure patient tumors, establish PDX tumor models and cryopreserve PDX tumor specimen.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Optimization efforts to procure patient tumors, establish PDX tumor models and cryopreserve PDX tumor specimen.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Comparative analysis of mutations in patient source tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Comparative analysis of mutations in patient source tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Validation of a EPB41L2::RAF1 gene fusion in an osteosarcoma PDX model.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Validation of a EPB41L2::RAF1 gene fusion in an osteosarcoma PDX model.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Evaluation of the EPB41L2::RAF1 gene fusion as an oncogenic driver and therapeutic target in osteosarcoma PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Evaluation of the EPB41L2::RAF1 gene fusion as an oncogenic driver and therapeutic target in osteosarcoma PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of sarcoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of sarcoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of osteosarcoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of osteosarcoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of neuroblastoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of neuroblastoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of Other Tumor cohort and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of Other Tumor cohort and corresponding PDX models.